

RESEARCH ARTICLE

Novel CSF biomarkers in genetic frontotemporal dementia identified by proteomics

Emma L. van der Ende^{1*}, Lieke H. Meeter^{1*}, Christoph Stingl², Jeroen G. J. van Rooij^{1,3}, Marcel P. Stoop², Diana A. T. Nijholt², Raquel Sanchez-Valle⁴, Caroline Graff^{5,6}, Linn Öijerstedt^{5,6}, Murray Grossman⁷, Corey McMillan⁷, Yolande A. L. Pijnenburg⁸, Robert Laforce Jr⁹, Giuliano Binetti^{10,11}, Luisa Benussi¹⁰, Roberta Ghidoni¹⁰, Theo M. Luider², Harro Seelaar¹ & John C. van Swieten¹

¹Department of Neurology, Erasmus Medical Center, PO Box 2040, 3015 GD Rotterdam, The Netherlands

²Laboratory of Neuro-oncology, Clinical and Cancer Proteomics, Department of Neurology, Erasmus Medical Center, PO Box 2040 3000 CA, Rotterdam, The Netherlands

³Department of Internal Medicine, Erasmus Medical Center, PO Box 2040, 3015 GD Rotterdam, The Netherlands

⁴Alzheimer's Disease and Other Cognitive Disorders Unit, Department of Neurology, Hospital Clínic, Institut d'Investigació Biomèdica August Pi i Sunyer, Villarroel, 170, 08036 Barcelona, Spain

⁵Division of Neurogeriatrics, Department NVS, Karolinska Institutet, Center for Alzheimer Research, Visionsgatan 4, 171 64 Solna Stockholm, Sweden

⁶Unit for Hereditary Dementias, Theme Aging, Karolinska University Hospital-Solna, 171 64 Stockholm, Sweden

⁷Department of Neurology, Penn Frontotemporal Degeneration Center, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania

⁸Alzheimer Center and Department of Neurology, Neuroscience Campus Amsterdam, VU University Medical Center, PO Box 7057, 1007 MB, Amsterdam, The Netherlands

⁹Clinique Interdisciplinaire de Mémoire (CIME), CHU de Québec, Département des Sciences Neurologiques, Université Laval, Québec, Québec, Canada

¹⁰Molecular Markers Laboratory, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, via Pilastroni 4, Brescia, 25125, Italy

¹¹MAC Memory Clinic, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, via Pilastroni 4, Brescia, 25125, Italy

Correspondence

John C. van Swieten, Erasmus Medical Center Rotterdam, Department of Neurology, Room Ee987f, PO Box 2040 3000 CA Rotterdam, The Netherlands.
Tel. +31 10 703 6477; Fax: +31 10 703 5927; E-mail: j.c.vanswieten@erasmusmc.nl

Funding Information

This study was supported in the Netherlands by two Memorabel grants from Deltaplan Dementie (The Netherlands Organisation for Health Research and Development and Alzheimer Nederland; grant numbers 733050813 and 733050103), the Bluefield Project to Cure Frontotemporal Dementia, the Dioraphte foundation (grant number 1402 1300), and the European Joint Programme – Neurodegenerative Disease Research and the Netherlands Organisation for Health Research and Development (PreFrontALS: 733051042, RiMod-FTD: 733051024); in Spain by the Spanish National Institute of Health Carlos III (ISCIII) under the aegis of the EU Joint Programme – Neurodegenerative Disease Research (JPND) (AC14/00013) and Fundacio Marato de TV3 (grant number 20143810); in Sweden by the

Abstract

Objective: To identify novel CSF biomarkers in *GRN*-associated frontotemporal dementia (FTD) by proteomics using mass spectrometry (MS). **Methods:** Unbiased MS was applied to CSF samples from 19 presymptomatic and 9 symptomatic *GRN* mutation carriers and 24 noncarriers. Protein abundances were compared between these groups. Proteins were then selected for validation if identified by ≥ 4 peptides and if fold change was ≤ 0.5 or ≥ 2.0 . Validation and absolute quantification by parallel reaction monitoring (PRM), a high-resolution targeted MS method, was performed on an international cohort ($n = 210$) of presymptomatic and symptomatic *GRN*, *C9orf72* and *MAPT* mutation carriers. **Results:** Unbiased MS revealed 20 differentially abundant proteins between symptomatic mutation carriers and noncarriers and nine between symptomatic and presymptomatic carriers. Seven of these proteins fulfilled our criteria for validation. PRM analyses revealed that symptomatic *GRN* mutation carriers had significantly lower levels of neuronal pentraxin receptor (NPTXR), receptor-type tyrosine-protein phosphatase N2 (PTPRN2), neurosecretory protein VGF, chromogranin-A (CHGA), and V-set and transmembrane domain-containing protein 2B (VSTM2B) than presymptomatic carriers and noncarriers. Symptomatic *C9orf72* mutation carriers had lower levels of NPTXR, PTPRN2, CHGA, and VSTM2B than noncarriers, while symptomatic *MAPT* mutation carriers had lower levels of NPTXR and CHGA than noncarriers. **Interpretation:** We identified and validated five novel CSF biomarkers in *GRN*-associated FTD. Our results show that synaptic, secretory vesicle, and inflammatory proteins are dysregulated in the symptomatic stage and may provide new insights

Swedish Alzheimer foundation, the Regional Agreement on Medical Training and Clinical Research (ALF) between Stockholm County Council and Karolinska Institutet, the Strategic Research Program in Neuroscience at Karolinska Institutet, Karolinska Institutet Doctoral Funding, Swedish Medical Research Council, Swedish Brain Foundation, the Old Servants foundation, Gun and Bertil Stohne's foundation and the Schörling Foundation – Swedish FTD Initiative; and in Italy by the Italian Ministry of Health (Ricerca Corrente).

Received: 20 December 2018; Revised: 5 February 2019; Accepted: 6 February 2019

***Annals of Clinical and Translational Neurology* 2019; 6(4): 698–707**

doi: 10.1002/acn3.745

*Authors contributed equally to the manuscript.

Introduction

Frontotemporal dementia (FTD) is the second most common form of presenile dementia, with autosomal dominant inheritance in approximately 30% of the cases.^{1,2} Pathogenic mutations in granulin (*GRN*) are a major cause of hereditary FTD with underlying transactive response DNA-binding protein 43 (TDP-43) pathology.² The vast majority of *GRN* mutations result in reduction of progranulin (PGRN) protein levels in blood and cerebrospinal fluid (CSF) by haploinsufficiency.^{3–6} However, the exact mechanism by which PGRN reduction leads to neurodegeneration is poorly understood. Upcoming therapeutic interventions should ideally be applied in the presymptomatic or prodromal stage of the disease, when neuronal damage is minimal, highlighting the need for biomarkers that reflect early pathological processes.⁷

Most studies on fluid biomarkers in FTD have used targeted approaches, allowing measurement of known protein candidates only,^{7,8} while unbiased approaches have scarcely been performed.^{9,10} In autosomal dominant Alzheimer's disease, unbiased approaches have uncovered early changes in the proteome.¹¹

In the present study, we investigated CSF proteomics by unbiased mass spectrometry (MS) in presymptomatic and symptomatic *GRN* mutation carriers. We aimed to identify novel proteins that reflect disease activity and/or give insight into the pathophysiology. We validated and quantified a selection of the identified proteins using parallel reaction monitoring (PRM), a high-resolution targeted MS-based approach, in an international cohort of

into the pathophysiology of genetic FTD. Further validation is needed to investigate their clinical applicability as diagnostic or monitoring biomarkers.

GRN mutation carriers and other forms of genetic FTD, namely *C9orf72* and *MAPT* mutation carriers.¹

Methods

Subjects

Discovery proteomics was applied on CSF of 9 symptomatic and 19 presymptomatic *GRN* mutation carriers and 24 healthy noncarriers (“discovery cohort”), who participate in the Dutch longitudinal FTD Risk Cohort (FTD-RisC).¹² Briefly, patients with genetic FTD and asymptomatic 50% at-risk individuals (either presymptomatic mutation carriers or noncarriers) from families with genetic FTD are followed yearly or two-yearly by means of neurological examination, neuropsychological testing, MRI scanning, structured informant interviews, and collection of blood and, in a subset, CSF collection.

PRM was performed on a selection of the proteins identified by discovery proteomics in CSF of 61 *GRN* mutation carriers (31 presymptomatic, 30 symptomatic), 70 *C9orf72* mutation carriers (16 presymptomatic, 54 symptomatic), 27 *MAPT* mutation carriers (12 presymptomatic, 15 symptomatic), and 52 noncarriers (“validation cohort”). CSF samples were collected from six research centers in Europe and the USA. Forty-six samples in the validation cohort overlapped with those in the discovery cohort.

The study was approved by the local ethics committee and all participants (or a legal representative) provided written informed consent.

Sample collection

CSF was collected in polypropylene tubes according to standardized local procedures and stored at -80°C after centrifugation within 2 h after withdrawal.

Discovery proteomics

Discovery proteomics was performed as described previously¹³ and details are reported in Data S2. In short, albumin and IgG were depleted from 50 μL of CSF sample to maximize peptide detection (Pierce, PN 85162). After overnight in-solution trypsin digestion, samples were analyzed by LC-MS/MS in a randomized order on a nano LC system coupled to an Orbitrap Fusion Lumos mass spectrometer (Thermo Fisher Scientific). For peptide and protein identification, MS/MS spectra were extracted using ProteoWizard¹⁴ software (version 3.0.9248) and analyzed with the database search engine Mascot (Matrix Science, UK) against the Uniprot database¹⁵ (downloaded November 12, 2015; taxonomy: *Homo sapiens*; 20,194 entries). Next we combined the search results of the individual samples, applied scoring of hits (local false discovery rate $\leq 1\%$), and conducted protein grouping using the software Scaffold.^{16,17} For label-free quantitation MS raw data were processed with Progenesis QI (version 2.0) and linked with identification results to finally determine peptide and protein abundances. Abundances were normalized to the total ion current to compensate for experimental variations using an algorithm available in the analysis software. Subsequently, the data were exported in Excel format.

Statistical analyses of discovery proteomics

For all peptides identified by discovery proteomics, we compared peptide abundances in: (1) symptomatic mutation carriers versus noncarriers; (2) symptomatic versus presymptomatic mutation carriers; (3) presymptomatic mutation carriers versus noncarriers. As the data were not normally distributed, a Wilcoxon rank-sum test was used. Corresponding proteins were regarded as significantly differentially abundant when they satisfied all of the following criteria, as described before¹⁸ with minor adjustments: (1) the protein was identified by two or more peptides; (2) 25% or more of the peptides of the protein were significant at $P < 0.01$; (3) 50% or more of the peptides of the protein were significant at $P < 0.05$; (4) 75% or more of the peptides were changed in the same direction (i.e., up- or downregulated). Statistical background levels were determined by permutation tests on all samples and all identified peptides/proteins. The number of differentially abundant proteins was regarded as significant when the

observed number in the true analysis exceeded the threshold from the permutation analysis: mean + three times the standard deviation. Fold changes based on median abundances were calculated for all group comparisons on peptide levels and peptides with a median of zero were excluded. Next, protein fold changes were calculated by the mean of corresponding peptide fold changes.

PRM validation

Differentially abundant proteins from discovery proteomics were selected for PRM validation based on the following criteria: (1) the protein was identified by four or more peptides and (2) protein fold change was ≤ 0.5 or ≥ 2.0 .

PRM was essentially performed as described previously¹⁹ and details are reported in Data S2. In short, 20 μL of CSF was digested overnight by trypsin. LC-MS analysis was carried out on a nano LC system coupled to an Orbitrap Fusion mass spectrometer (Thermo Fisher Scientific). For PRM of the peptide panel of candidates a time scheduled targeted MS/MS method was used and the referring peptide-specific parameters are listed in Table S1. To allow absolute quantification of peptides, synthetic stable isotope labeled (SIL) peptides were added as listed in Table S1. As technical quality check (QC), a pool of 80 CSF samples was prepared and loaded as 8-fold replicate on each well-plate. During LC-MS measurements, every 12th run a QC sample was measured to determine the reproducibility of the assay. For assessment of sensitivity of the assay an eight-point dilutions series of the peptide panel in CSF digest matrix was prepared and measured in triplicate. MS data processing was conducted using the software package Skyline.²⁰ Peak ratios were exported and used for calculation of CSF concentrations of the samples and determining analytical parameters limit of detection (LOD), lower limit of quantitation (LLOQ), and coefficients of variance (CV) (Tables S2a and S2b) using the software package R.²¹

Statistical analyses of demographic data and PRM validation

Statistical analyses were performed in IBM SPSS Statistics 24.0 applying a significance level of $P < 0.05$. Demographic and PRM data for each genotype (*GRN*, *C9orf72*, and *MAPT*) were compared between symptomatic mutation carriers, presymptomatic mutation carriers, and noncarriers. For PRM results, per candidate protein one corresponding targeted peptide was chosen based on the suitability for quantification and lowest LOD, LLOQ, and CV as indicated in Tables S2a and S2b. Peptides with CV $> 15\%$ were excluded from further analyses. As the data

were not normally distributed, a Kruskal-Wallis test with post hoc Dunn's test was performed to compare peptide concentrations between groups. Analysis of covariance (ANCOVA) of log-transformed peptide concentrations was used to correct for age at CSF sampling. All post hoc analyses were adjusted for multiple testing by means of Bonferroni correction.

Mass spectrometry data has been made available via the PRIDE partner repository with the dataset identifiers PXD012178 (discovery study) and PXD012179 (validation study).²²

Gene set enrichment analyses

Gene set enrichment analyses to the Gene Ontology database²³ were performed on a selection of proteins identified by discovery proteomics in symptomatic mutation carriers versus noncarriers, and separately on proteins identified in symptomatic versus presymptomatic mutation carriers. We relaxed the protein selection criteria to allow for separation of multiple enriched pathways in our dataset, aiming to include 50–150 proteins per enrichment analysis. Proteins with a fold change ≤ 0.83 or ≥ 1.2 and with $\geq 25\%$ of the peptides significantly up- or down-regulated ($P < 0.05$) were included. Enrichment was performed to the whole genome as statistical background, accepting false discovery rate (FDR)-corrected results of $P < 0.05$ as significantly enriched Gene Ontology (GO) terms. The most significant nonredundant terms for Biological Processes (GOBP), Cellular Components (GOCC), and Molecular Functions (GOMF) were extracted and a protein network was created based on these terms using Cytoscape (v3.4.0).

Results

Subjects

Subject characteristics are shown in Table 1. In the discovery cohort, no differences were found in age at CSF collection or gender among symptomatic and presymptomatic mutation carriers and noncarriers. In the validation cohort, symptomatic *GRN* (median 61 years) and *C9orf72* mutation carriers (59 years) were significantly older than presymptomatic *GRN* (54 years) and *C9orf72* mutation carriers (45 years, both $P < 0.001$) and noncarriers (54 years, $P < 0.001$) at the time of CSF collection.

Discovery proteomics

We identified a total of 4539 peptides corresponding to 572 proteins, of which 503 proteins were identified by ≥ 2 peptides. Twenty proteins were considered significantly differentially abundant in symptomatic *GRN* mutation carriers compared to noncarriers. In the comparison between symptomatic and presymptomatic *GRN* mutation carriers, nine differentially abundant proteins were found (Fig. 1, Table S3). No significant differences were found between presymptomatic *GRN* mutation carriers and noncarriers. All differentially abundant proteins were identified by peptides, which were matched exclusively to that protein.

Validation by PRM

Seven proteins fulfilled our criteria for validation by PRM (Table 2). The protein Ig alpha-1 chain C region (IGHA1)

Table 1. Subject characteristics.

	N	Age at CSF collection, years	Gender, male (%)	Age at symptom onset, years	Disease duration, years
Discovery cohort					
Noncarriers	24	51 (40–58)	14 (58%)	n/a	n/a
Presymptomatic <i>GRN</i>	19	56 (47–60)	9 (47%)	n/a	n/a
Symptomatic <i>GRN</i>	9	58 (53–60)	3 (33%)	57 (51–58)	2.3 (1.5–3.6)
Validation cohort					
Noncarriers	52	54 (43–59)	24 (46%)	n/a	n/a
Presymptomatic <i>GRN</i>	31	54 (42–59)	12 (39%)	n/a	n/a
Symptomatic <i>GRN</i>	30	61 (57–66)*	11 (37%)	58 (55–63)	1.9 (1.2–3.0)
Presymptomatic <i>C9orf72</i>	16	45(36–52)	3 (19%)	n/a	n/a
Symptomatic <i>C9orf72</i>	54	59 (54–65)†	31 (57%)‡	56 (50–62)	2.4 (1.2–5.2)
Presymptomatic <i>MAPT</i>	12	48 (44–53)	5 (42%)	n/a	n/a
Symptomatic <i>MAPT</i>	15	53 (51–60)	7 (47%)	51 (46–55)	3.0 (1.4–5.0)

Continuous variables are presented as medians (interquartile range). FTD, frontotemporal dementia; CSF, cerebrospinal fluid.

*Symptomatic *GRN* mutation carriers significantly older than presymptomatic *GRN* mutation carriers and noncarriers ($P < 0.001$).

†Symptomatic *C9orf72* mutation carriers significantly older than presymptomatic *C9orf72* mutation carriers and noncarriers ($P < 0.001$).

‡Symptomatic *C9orf72* mutation carriers and noncarriers significantly more males than presymptomatic *C9orf72* mutation carriers ($P = 0.024$).




Figure 1. Flow chart of differentially abundant proteins. The number of identified peptides and proteins are displayed and are then split to the differentially abundant proteins per group comparison: (1) symptomatic versus presymptomatic carriers, and (2) symptomatic versus noncarriers. No differentially abundant proteins were found in the comparison presymptomatic versus noncarriers (not shown). In the lower row, proteins are displayed that were selected for validation by PRM. CaM, Calcium/calmodulin-dependent; NPTXR, neuronal pentraxin receptor; PTPRN, receptor-type tyrosine-protein phosphatase-like N; PTPRN2, receptor-type tyrosine-protein phosphatase N2; TNF, tumor necrosis factor; VSTM2B, V-set and transmembrane domain-containing protein 2B.

was excluded from validation analyses as just one peptide was targeted and this peptide had a CV>15%.

Symptomatic *GRN* mutation carriers had significantly lower concentrations of Neuronal pentraxin receptor (NPTXR), Receptor-type tyrosine-protein phosphatase N2 (PTPRN2), Neurosecretory protein VGF (VGF), Chromogranin-A (CHGA), and V-set transmembrane

domain-containing protein (VSTM2B) compared to both presymptomatic carriers and noncarriers by PRM (Table 3, Fig. 2, Fig. S1). Complement component C8 gamma chain (C8G) levels were higher in symptomatic mutation carriers, however, this difference was no longer statistically significant after correction for age at CSF sampling.

Table 2. Proteins selected for validation by PRM.

	Peptides, <i>n</i>	Fold change (SYM/MNC)	Fold change (SYM/PRE)
NPTXR	6	0.34	0.39
PTPRN2	5	0.35	–
VGF	21	0.45	–
CHGA	18	0.46	–
VSTM2B	4	0.49	–
C8G	4	2.00	–
IGHA1	6	2.39	–

Fold change (SYM/MNC): fold change in discovery proteomics in the comparison between symptomatic *GRN* mutation carriers and noncarriers. Fold change (SYM/PRE): fold change in discovery proteomics in the comparison between symptomatic and presymptomatic *GRN* mutation carriers. NPTXR, neuronal pentraxin receptor; PTPRN2, receptor-type tyrosine-protein phosphatase N2; VGF, neurosecretory protein VGF; CHGA, chromogranin-A; VSTM2B, V-set and transmembrane domain-containing protein 2B; C8G, complement component C8 gamma chain; IGHAI, Ig alpha-1 chain C region.

Symptomatic *C9orf72* mutation carriers had significantly lower concentrations of NPTXR, PTPRN2, CHGA, and VSTM2B compared to noncarriers (Fig. 2, Fig. S1). Lower concentrations of NPTXR, PTPRN2, CHGA, and VSTM2B were found in presymptomatic mutation carriers than in noncarriers, although not statistically significant.

Symptomatic *MAPT* mutation carriers had significantly lower concentrations of NPTXR and CHGA compared to noncarriers, while the other proteins did not show any significant differences between groups (Fig. 2, Fig. S1).

For all proteins included in validation analyses, no significant differences were found between presymptomatic carriers and noncarriers.

Gene set enrichment analyses

For gene set enrichment analyses, 116 proteins were included in the comparison of symptomatic mutation carriers versus noncarriers, and 72 proteins were included in the comparison of symptomatic versus presymptomatic mutation carriers. In total, 44 GOBP and 7 GOCC terms were significantly enriched (Data S1). The most significantly enriched terms for both comparisons included acute inflammatory response, response to axonal injury and modulation of synaptic transmission. The generated protein interaction network is shown in Figure S2.

Discussion

In this proteomics study, we identified several differentially regulated proteins in CSF of *GRN*-associated FTD. Validation of our results by targeted mass spectrometry revealed significantly lower levels of NPTXR, CHGA, VSTM2B, PTPRN2, and VGF in symptomatic *GRN* mutation carriers compared to presymptomatic and noncarriers. Here, we provide some background information on these proteins.

NPTXR is a transmembrane protein expressed on neurons and glia and is a member of the neuronal pentraxin (NP) family. NPs are multifunctional proteins that have been implicated in synaptic plasticity.^{24,25} NPTXR has been identified as a progression biomarker in Alzheimer's disease (AD), with elevated levels in mild cognitive impairment and low levels in AD patients.^{26–29} In autosomal dominant AD, NPTXR levels were elevated in presymptomatic carriers,¹¹ an effect we did not observe in our presymptomatic *GRN* carriers. This discrepancy may result from differences in underlying pathophysiology, or

Table 3. Protein levels measured by PRM in *GRN* mutation carriers.

	Symptomatic carriers (ng/ml) [IQR] (<i>n</i> = 30)	Presymptomatic carriers (ng/ml) [IQR] (<i>n</i> = 31)	Noncarriers (ng/ml) [IQR] (<i>n</i> = 52)	<i>P</i> -value
NPTXR	89.1 [68.3–117.2]	138.2 [114.2–171.0]	148.4 [118.2–167.0]	<0.001*
PTPRN2	8.7 [6.6–10.8]	15.1 [12.1–17.7]	13.6 [10.9–17.2]	<0.001**
VGF	117.6 [78.3–167.9]	203.3 [158.4–273.0]	171.7 [129.5–228.9]	<0.001†
CHGA	286.5 [233.6–343.6]	409.2 [293.6–471.9]	416.0 [337.7–509.6]	<0.001*
VSTM2B	13.6 [11.0–16.2]	17.7 [13.6–21.3]	17.7 [15.4–21.9]	<0.001‡
C8G	14.2 [10.2–20.6]	13.0 [9.2–17.5]	10.0 [7.9–15.6]	0.126

Peptides used for quantification are indicated in Table S2. *P*-values for analyses of covariance (correcting for age at CSF sampling) and after correction for multiple testing are displayed. NPTXR, neuronal pentraxin receptor; PTPRN2, receptor-type tyrosine-protein phosphatase N2; VGF, neurosecretory protein VGF; CHGA, chromogranin-A; VSTM2B, V-set and transmembrane domain-containing protein 2B; C8G, complement component C8 gamma chain.

*Symptomatic *GRN* mutation carriers versus noncarriers *P* < 0.001; symptomatic versus presymptomatic *GRN* mutation carriers *P* < 0.001.

**Symptomatic *GRN* mutation carriers versus noncarriers *P* = 0.002; symptomatic versus presymptomatic *GRN* mutation carriers *P* < 0.001.

†Symptomatic *GRN* mutation carriers versus noncarriers *P* = 0.045; symptomatic versus presymptomatic *GRN* mutation carriers *P* = 0.005.

‡Symptomatic *GRN* mutation carriers versus noncarriers *P* = 0.002; symptomatic versus presymptomatic *GRN* mutation carriers *P* = 0.007.




Figure 2. Neuronal pentraxin receptor (NPTXR) in presymptomatic and symptomatic *GRN*, *C9orf72* and *MAPT* mutation carriers by PRM. Error bars represent medians with interquartile ranges. Significances from the analysis of covariance (corrected for age at CSF sampling) and after correction for multiple testing are displayed. * $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$.

because we studied presymptomatic carriers of all ages and thus of varying time from onset.

VGF and CHGA belong to the granin protein family and are precursors of peptides with numerous biological functions, including microglial activation (CHGA) and synaptic plasticity.^{30–32} Decreased VGF and CHGA levels were also found in proteomics studies in AD.^{11,26,29,33}

PTPRN2 is a transmembrane protein present in dense-core vesicles, implicated in secretory processes in the pancreatic islets, but also in the brain.³⁴ PTPRN, a highly homologous protein, was also found in our discovery proteomics, although it did not strictly fulfill our criteria for validation (fold change 0.56). PTPRN2 is also involved in secretory processes and is decreased in CSF of AD patients.²⁸ Both PTPRN2 and PTPRN also play more general roles in secretion of hormones and neurotransmitters, and knockdown of both these proteins result in behavioral and learning impairments in mice.³⁴

C8G, a constituent of innate immunity was elevated in symptomatic *GRN* mutation carriers compared to noncarriers, although not statistically significant after correction for covariates.³⁵ An important role for inflammatory pathways in FTD is supported by prior studies that identified YKL-40, complement factors and interleukines as candidate biomarkers for FTD. The numerous enriched gene ontology terms related to inflammatory processes support this hypothesis. PGRN is implicated as an anti-inflammatory protein, with haploinsufficiency resulting in lysosomal dysfunction, complement production and microglial activation.³⁶

The last candidate protein we identified is VSTM2B, this is a membrane protein but its exact function has scarcely been studied.

The observed decrease in synapse proteins could represent synaptic turnover or loss occurring during the course of the disease. Increasing evidence suggests that altered synaptic function may contribute to the early pathogenesis of FTD, especially in *GRN* mutations,^{36–38} a concept previously recognized primarily in AD. In rat hippocampal neurons, knocking down PGRN decreases synapse density,³⁹ and in *GRN*-knockout mice, PGRN-deficiency causes synaptic dysfunction prior to the occurrence of other neuropathological changes.⁴⁰ It has been hypothesized that PGRN deficiency could cause synaptic pruning through activation of microglia and complement factors.³⁶ Strategies aimed at increasing or maintaining synaptic connectivity could prove beneficial in future therapeutic interventions.

Four of the five protein decreases (NPTXR, VSTM2B, CHGA, and PTPRN2) observed in symptomatic *GRN* carriers were also seen in symptomatic *C9orf72* carriers, suggesting that these changes are not specific for *GRN*-associated FTD. The trend toward lower levels of these proteins in presymptomatic *C9orf72* carriers compared to noncarriers, must be interpreted with caution due to the lack of statistical significance. However, if confirmed in a larger genetic FTD cohort, this could support the hypothesis that *C9orf72*-associated FTD has a more protracted onset than *GRN*-associated FTD.^{41–43} In *MAPT* mutation carriers, significant differences in protein concentrations were only found for NPTXR and CHGA. This may reflect differences in underlying pathophysiology or it may be due to the smaller sample size in *MAPT* mutation carriers.^{2,7}

Strengths of this study include the unique sample set with a large cohort of presymptomatic and symptomatic *GRN* mutation carriers. Restricting our discovery cohort to *GRN* mutation carriers allowed us to create a pathologically homogeneous group of FTD-patients. The unbiased proteomics approach enabled us to identify novel biomarkers without predefined hypotheses. Validation of our discovery proteomics results by PRM has provided convincing evidence for our findings.

The depletion step in the discovery proteomics, removing albumin, and IgG, has considerably improved the detection of low abundance proteins. Very low abundance proteins could, however, be below the detection limit despite the depletion step. This may explain why we did not find PGRN, known to be decreased in *GRN* mutation carriers, or neurofilament light chain (NfL), known to be increased in symptomatic carriers, both of which have average CSF concentrations below 10 ng/ml.^{4,41} Furthermore, relevant proteins may bind to the depleted proteins,

thereby impeding their detection.⁴⁴ Finally, our stringent selection criteria for validation likely reduced the number of false-positive findings, however, may also have excluded certain relevant potential biomarkers.

In conclusion, we present five promising novel CSF biomarkers in genetic FTD. Further verification and correlation with clinical features is needed in larger cohorts of genetic FTD, such as GENFI (Genetic FTD Initiative) and LEFFTDS (Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects). Validation by immunoassays is necessary to reveal whether clinical implementation of these biomarkers is feasible.

Acknowledgments

We are greatly indebted to all participants of this study. We thank all local research coordinators for their help in collecting CSF samples and clinical data. This study was supported in the Netherlands by two Memorabel grants from Deltaplan Dementie (The Netherlands Organisation for Health Research and Development and Alzheimer Nederland; grant numbers 733050813 and 733050103), the Bluefield Project to Cure Frontotemporal Dementia, the Dioraphte foundation (grant number 1402 1300), and the European Joint Programme – Neurodegenerative Disease Research and the Netherlands ORganisation for Health Research and Development (PreFrontALS: 733051042, RiMod-FTD: 733051024); in Spain by the Spanish National Institute of Health Carlos III (ISCIII) under the aegis of the EU Joint Programme – Neurodegenerative Disease Research (JPND) (AC14/00013) and Fundacio Marato de TV3 (grant number 20143810); in Sweden by the Swedish Alzheimer foundation, the Regional Agreement on Medical Training and Clinical Research (ALF) between Stockholm County Council and Karolinska Institutet, the Strategic Research Program in Neuroscience at Karolinska Institutet, Karolinska Institutet Doctoral Funding, Swedish Medical Research Council, Swedish Brain Foundation, the Old Servants foundation, Gun and Bertil Stohne's foundation and the Schörling Foundation – Swedish FTD Initiative; and in Italy by the Italian Ministry of Health (Ricerca Corrente).

Author Contributions

E.L.v.d.E. and L.H.M. contributed to study design, data acquisition, statistical analysis and interpretation, and drafting of the manuscript. C.S., M.P.S., and D.N. contributed to data acquisition and analysis (i.e., mass spectrometry experiments) and drafting of the manuscript. J.G.J.v.R. contributed to study design, data analysis and interpretation (i.e., gene set enrichment analysis) and drafting of the manuscript. J.C.v.S., H.S., and T.M.L.

contributed to study design, data acquisition and interpretation, and provided critical revision of the manuscript. All other authors contributed to data acquisition and revised the manuscript.

Conflict of Interest

The authors report no conflict of interest relevant to this work.

References

- Lashley T, Rohrer JD, Mead S, Revesz T. Review: an update on clinical, genetic and pathological aspects of frontotemporal lobar degenerations. *Neuropathol Appl Neurobiol* 2015;41:858–881.
- Seelaar H, Rohrer JD, Pijnenburg YAL, et al. Clinical, genetic and pathological heterogeneity of frontotemporal dementia: a review. *J Neurol Neurosurg Psychiatry* 2011;82:476–486.
- Ghidoni R, Benussi L, Glionna M, et al. Low plasma progranulin levels predict progranulin mutations in frontotemporal lobar degeneration. *Neurology* 2008;71:1235–1239.
- Meeter LH, Patzke H, Loewen G, et al. Progranulin levels in plasma and cerebrospinal fluid in granulin mutation carriers. *Dement Geriatr Cogn Dis Extra* 2016;6:330–340.
- Eriksen JL, Mackenzie IR. Progranulin: normal function and role in neurodegeneration. *J Neurochem* 2008;104:287–297.
- Sleegers K, Brouwers N, Van Damme P, et al. Serum biomarker for progranulin-associated frontotemporal lobar degeneration. *Ann Neurol* 2009;65:603–609.
- Meeter LH, Kaat LD, Rohrer JD, van Swieten JC. Imaging and fluid biomarkers in frontotemporal dementia. *Nat Rev Neurol* 2017;13:406–419.
- Oeckl P, Steinacker P, Feneberg E, Otto M. Cerebrospinal fluid proteomics and protein biomarkers in frontotemporal lobar degeneration: current status and future perspectives. *Biochim Biophys Acta* 2015;1854:757–768.
- Teunissen CE, Elias N, Koel-Simmelink MJ, et al. Novel diagnostic cerebrospinal fluid biomarkers for pathologic subtypes of frontotemporal dementia identified by proteomics. *Alzheimers Dement (Amst)* 2016;2:86–94.
- Agresta AM, De Palma A, Bardoni A, et al. Proteomics as an innovative tool to investigate frontotemporal disorders. *Proteomics Clin Appl* 2016;10:457–469.
- Ringman JM, Schulman H, Becker C, et al. Proteomic changes in cerebrospinal fluid of presymptomatic and affected persons carrying familial Alzheimer disease mutations. *Arch Neurol* 2012;69:96–104.
- Dopper EG, Rombouts SA, Jiskoot LC, et al. Structural and functional brain connectivity in presymptomatic familial frontotemporal dementia. *Neurology* 2014;83:e19–e26.

13. Stoop MP, Singh V, Stingl C, et al. Effects of natalizumab treatment on the cerebrospinal fluid proteome of multiple sclerosis patients. *J Proteome Res* 2013;12:1101–1107.
14. Chambers MC, Maclean B, Burke R, et al. A cross-platform toolkit for mass spectrometry and proteomics. *Nat Biotechnol* 2012;30:918–920.
15. UniProt Consortium T. UniProt: the universal protein knowledgebase. *Nucleic Acids Res* 2018;46:2699.
16. Nesvizhskii AI, Keller A, Kolker E, Aebersold R. A statistical model for identifying proteins by tandem mass spectrometry. *Anal Chem* 2003;75:4646–4658.
17. Hather G, Higdon R, Bauman A, et al. Estimating false discovery rates for peptide and protein identification using randomized databases. *Proteomics* 2010;10:2369–2376.
18. van den Berg CB, Duvekot JJ, Guzel C, et al. Elevated levels of protein AMBP in cerebrospinal fluid of women with preeclampsia compared to normotensive pregnant women. *Proteomics Clin Appl* 2017;11. <https://doi.org/10.1002/prca.201600082>
19. Guzel C, Govorukhina NI, Wisman GBA, et al. Proteomic alterations in early stage cervical cancer. *Oncotarget* 2018;9:18128–18147.
20. MacLean B, Tomazela DM, Shulman N, et al. Skyline: an open source document editor for creating and analyzing targeted proteomics experiments. *Bioinformatics* 2010;26:966–968.
21. R Development Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2013.
22. Vizcaino JA, Csordas A, del-Toro N, et al. update of the PRIDE database and its related tools. *Nucleic Acids Res* 2016;2016:D447–D456.
23. Gene Ontology C. Creating the gene ontology resource: design and implementation. *Genome Res* 2001;11:1425–1433.
24. Osera C, Pascale A, Amadio M, et al. Pentraxins and Alzheimer's disease: at the interface between biomarkers and pharmacological targets. *Ageing Res Rev* 2012;11:189–198.
25. Xiao MF, Xu D, Craig MT, et al. NPTX2 and cognitive dysfunction in Alzheimer's Disease. *Elife* 2017;23:6.
26. Hendrickson RC, Lee AY, Song Q, et al. High resolution discovery proteomics reveals candidate disease progression markers of Alzheimer's disease in human cerebrospinal fluid. *PLoS ONE* 2015;10:e0135365.
27. Wildsmith KR, Schauer SP, Smith AM, et al. Identification of longitudinally dynamic biomarkers in Alzheimer's disease cerebrospinal fluid by targeted proteomics. *Mol Neurodegener* 2014;6:22.
28. Llano DA, Bundela S, Mudar RA, et al. A multivariate predictive modeling approach reveals a novel CSF peptide signature for both Alzheimer's Disease state classification and for predicting future disease progression. *PLoS ONE* 2017;12:e0182098.
29. Spellman DS, Wildsmith KR, Honigberg LA, et al. Development and evaluation of a multiplexed mass spectrometry based assay for measuring candidate peptide biomarkers in Alzheimer's Disease Neuroimaging Initiative (ADNI) CSF. *Proteomics Clin Appl* 2015;9:715–731.
30. Bartolomucci A, Possenti R, Mahata SK, et al. The extended granin family: structure, function, and biomedical implications. *Endocr Rev* 2011;32:755–797.
31. Toshinai K, Nakazato M. Neuroendocrine regulatory peptide-1 and -2: novel bioactive peptides processed from VGF. *Cell Mol Life Sci* 2009;66:1939–1945.
32. Heneka MT, Kummer MP, Latz E. Innate immune activation in neurodegenerative disease. *Nat Rev Immunol* 2014 1;14:463–477.
33. Brinkmalm G, Sjodin S, Simonsen AH, et al. A parallel reaction monitoring mass spectrometric method for analysis of potential CSF biomarkers for Alzheimer's disease. *Proteomics Clin Appl* 2018;12:1–2.
34. Cai T, Notkins AL. Pathophysiologic changes in IA-2/IA-2beta null mice are secondary to alterations in the secretion of hormones and neurotransmitters. *Acta Diabetol* 2016;53:7–12.
35. Bayly-Jones C, Bubeck D, Dunstone MA. The mystery behind membrane insertion: a review of the complement membrane attack complex. *Philos Trans R Soc Lond B Biol Sci* 2017;372:1–2.
36. Lui H, Zhang J, Makinson SR, et al. Progranulin deficiency promotes circuit-specific synaptic pruning by microglia via complement activation. *Cell* 2016;165:921–935.
37. Petkau TL, Leavitt BR. Progranulin in neurodegenerative disease. *Trends Neurosci* 2014;37:388–398.
38. Marttinen M, Kurkinen KM, Soininen H, et al. Synaptic dysfunction and septin protein family members in neurodegenerative diseases. *Mol Neurodegener* 2015;3:16.
39. Tapia L, Milnerwood A, Guo A, et al. Progranulin deficiency decreases gross neural connectivity but enhances transmission at individual synapses. *J Neurosci* 2011;31:11126–11132.
40. Petkau TL, Neal SJ, Milnerwood A, et al. Synaptic dysfunction in progranulin-deficient mice. *Neurobiol Dis* 2012;45:711–722.
41. Meeter LH, Doppert EG, Jiskoot LC, et al. Neurofilament light chain: a biomarker for genetic frontotemporal dementia. *Ann Clin Transl Neurol* 2016;3:623–636.
42. Rohrer JD, Nicholas JM, Cash DM, et al. Presymptomatic cognitive and neuroanatomical changes in genetic frontotemporal dementia in the Genetic Frontotemporal Dementia Initiative (GENFI) study: a cross-sectional analysis. *Lancet Neurol* 2015;14:253–262.
43. Jiskoot LC, Bocchetta M, Nicholas JM, et al. Presymptomatic white matter integrity loss in familial frontotemporal dementia in the GENFI cohort: a cross-

sectional diffusion tensor imaging study. *Ann Clin Transl Neurol* 2018;5:1025–1036.

44. Gunther R, Krause E, Schumann M, et al. Depletion of highly abundant proteins from human cerebrospinal fluid: a cautionary note. *Mol Neurodegener* 2015;15:53.

Supporting Information

Additional supporting information may be found online in the Supporting Information section at the end of the article.

Figure S1. Protein levels measured by PRM in presymptomatic and symptomatic GRN, C9orf72 and MAPT mutation carriers.

Figure S2. Network of enriched Gene Ontology (GO) terms coupled to related proteins.

Data S1. List of enriched Gene Ontology terms.

Data S2. Methods

Table S1. Peptide specific settings of the PRM method.

Table S2a. PRM settings: Peptide assay characteristics.

Table S2b. Peptide quantification information.

Table S3a. Differentially abundant proteins ($n = 20$) in symptomatic GRN mutation carriers versus noncarriers.

Table S3b. Differentially abundant proteins ($n = 9$) in symptomatic versus presymptomatic GRN mutation carriers.